Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Raises $4M

NEW YORK (GenomeWeb News) – Molecular diagnostics company Biodesix said in a regulatory document that it has raised about $4 million in a private financing.

The company did not respond to requests for comment, but in its Form D filed with the US Securities and Exchange Commission on Tuesday, Biodesix said that the type of securities offered were options, warrants, or other rights to acquire another security; security to be acquired upon the exercise of an option, warrant, or other right to acquire security; and promissory notes that may be converted into Biodesix's equity securities.

It did not identify the investors or say how the financing will be used.

In April 2012, the Boulder, Colo.-based firm raised $8.8 million in a follow-on sale of its Series D preferred shares. It also raised $12 million in a Series D extension in August 2012.

Four months ago, Biodesix said Medicare would cover its VeriStrat proteomic lung cancer test.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.